Teriparatide improves volumetric bone mineral density and fine bone structure in the UIV+1 vertebra, and reduces bone failure type PJK after surgery for adult spinal deformity.

Yagi M, Ohne H, Konomi T, Fujiyoshi K, Kaneko S, Komiyama T, Takemitsu M, Yato Y, Machida M, Asazuma T

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA24 Jun 2016Cited by 103 (Europe PMC)

PMID27341809DOI10.1007/s00198-016-3676-6PepBankPUB-27341809

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanObservational studyEfficacy outcome
After spinal deformity surgery, hip BMD increased with teriparatide but decreased in controls, with significantly different percentage changes.
In plain wordsAfter spinal deformity surgery, hip bone density increased with teriparatide but decreased without it.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseHip BMD
Study
n = 76
Comparator
No teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Hip BMD
0.721 g/cm2
TP group, baseline
Hip BMD
0.771 g/cm2
TP group, after 6 months
Hip BMD
0.759 g/cm2
control group, baseline
Hip BMD
0.729 g/cm2
control group, after 6 months
Source sentences
Summary
After 6 months of treatment, mean hip-bone mineral density (BMD) increased from 0.721 to 0.771 g/cm² in the TP group and decreased from 0.759 to 0.729 g/cm² in the control group.
3 context sentences(design, population, supporting numbers)
Summary · context
This percent BMD change between groups was significant (p < 0.05).
Summary · context
Forty-three patients who started TP therapy immediately after surgery and 33 patients who did not receive TP were enrolled in this prospective case series.
Summary · context
These patients were female, over 50, surgically treated for ASD, and followed for at least 2 years.
Report a problemFND-2734180901
02HumanObservational studyEfficacy outcome
After spinal deformity surgery, PJK type 2 incidence at 2 years was 4.6% with teriparatide versus 15.2% in controls.
In plain wordsAfter spinal deformity surgery, vertebral-failure-type junctional kyphosis occurred less often with teriparatide than without it.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasePJK type 2 incidence
Study
n = 76
Comparator
No teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
PJK type 2 incidence
4.6%
TP group, 2-year follow-up
PJK type 2 incidence
15.2%
control group, 2-year follow-up
Source sentences
Summary
At the 2-year follow-up, the PJK type 2 incidence was significantly lower in the TP group (4.6 %) than in the control group (15.2 %; p = .02).
2 context sentences(design, population, supporting numbers)
Summary · context
Forty-three patients who started TP therapy immediately after surgery and 33 patients who did not receive TP were enrolled in this prospective case series.
Summary · context
These patients were female, over 50, surgically treated for ASD, and followed for at least 2 years.
Report a problemFND-2734180907
03HumanObservational studyEfficacy outcome
After spinal deformity surgery, teriparatide treatment was linked to increased UIV+1 volumetric BMD from 326 to 366 mg/cm3.
In plain wordsAfter spinal deformity surgery, bone density above the instrumented vertebra increased from baseline with teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseUIV+1 volumetric BMD
Study
n = 43
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
UIV+1 volumetric BMD
326 mg/cm3
TP group, before surgery
UIV+1 volumetric BMD
366 mg/cm3
TP group, 6 months after surgery
Source sentences
Summary
The volumetric BMD (326 to 366 mg/cm³) and bone mineral content (BMC) (553 to 622 mg) at UIV+1 were also significantly increased in TP group.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty-three patients who started TP therapy immediately after surgery and 33 patients who did not receive TP were enrolled in this prospective case series.
Summary · context
These patients were female, over 50, surgically treated for ASD, and followed for at least 2 years.
Report a problemFND-2734180902
04HumanObservational studyEfficacy outcome
After spinal deformity surgery, teriparatide treatment was linked to increased UIV+1 bone mineral content from 553 to 622 mg.
In plain wordsAfter spinal deformity surgery, bone mineral content above the instrumented vertebra increased from baseline with teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseUIV+1 bone mineral content
Study
n = 43
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
UIV+1 bone mineral content
553 mg
TP group, before surgery
UIV+1 bone mineral content
622 mg
TP group, 6 months after surgery
Source sentences
Summary
The volumetric BMD (326 to 366 mg/cm³) and bone mineral content (BMC) (553 to 622 mg) at UIV+1 were also significantly increased in TP group.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty-three patients who started TP therapy immediately after surgery and 33 patients who did not receive TP were enrolled in this prospective case series.
Summary · context
These patients were female, over 50, surgically treated for ASD, and followed for at least 2 years.
Report a problemFND-2734180903
05HumanObservational studyEfficacy outcome
After spinal deformity surgery, bone volume/tissue volume increased from 46 to 54% during teriparatide treatment.
In plain wordsAfter spinal deformity surgery, bone volume relative to tissue volume increased from baseline with teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone volume/tissue volume ratio
Study
n = 43
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Bone volume/tissue volume ratio
46%
TP group, before surgery
Bone volume/tissue volume ratio
54%
TP group, 6 months after surgery
Source sentences
Summary
The bone volume/tissue volume ratio increased from 46 to 54 % in the TP group, and the trabecular bone thickness and number increased by 14 and 5 %, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty-three patients who started TP therapy immediately after surgery and 33 patients who did not receive TP were enrolled in this prospective case series.
Summary · context
These patients were female, over 50, surgically treated for ASD, and followed for at least 2 years.
Report a problemFND-2734180904
06HumanObservational studyEfficacy outcome
After spinal deformity surgery, trabecular thickness increased by 14% during teriparatide treatment.
In plain wordsAfter spinal deformity surgery, bone trabeculae became thicker than at baseline with teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular thickness
Study
n = 43
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Increase in trabecular bone thickness
14%
TP group
Source sentences
Summary
The bone volume/tissue volume ratio increased from 46 to 54 % in the TP group, and the trabecular bone thickness and number increased by 14 and 5 %, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty-three patients who started TP therapy immediately after surgery and 33 patients who did not receive TP were enrolled in this prospective case series.
Summary · context
These patients were female, over 50, surgically treated for ASD, and followed for at least 2 years.
Report a problemFND-2734180905
07HumanObservational studyEfficacy outcome
After spinal deformity surgery, trabecular number increased by 5% during teriparatide treatment.
In plain wordsAfter spinal deformity surgery, the number of bone trabeculae increased from baseline with teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular number
Study
n = 43
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Increase in trabecular number
5%
TP group
Source sentences
Summary
The bone volume/tissue volume ratio increased from 46 to 54 % in the TP group, and the trabecular bone thickness and number increased by 14 and 5 %, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty-three patients who started TP therapy immediately after surgery and 33 patients who did not receive TP were enrolled in this prospective case series.
Summary · context
These patients were female, over 50, surgically treated for ASD, and followed for at least 2 years.
Report a problemFND-2734180906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.